Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Scherpereel, A., Grigoriu, B., Conti, M., Gey, T., Gregoire, M., Copin, M., Devos, P., Chahine, B., Porte, H., & Lassalle, P. American journal of respiratory and critical care medicine, 173(10):1155–1160, May, 2006.
doi  abstract   bibtex   
BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma. FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L). The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L). The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%). The AUC for pleural
@article{scherpereel_soluble_2006,
	title = {Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.},
	volume = {173},
	issn = {1073-449X 1073-449X},
	doi = {10.1164/rccm.200511-1789OC},
	abstract = {BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma. FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L). The area under the receiver operating characteristic curve  (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80\%, specificity = 82.6\%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3\%, specificity = 73.3\%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L;  benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L). The AUC for  pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7\%, specificity = 76.2\%). The AUC for pleural},
	language = {eng},
	number = {10},
	journal = {American journal of respiratory and critical care medicine},
	author = {Scherpereel, Arnaud and Grigoriu, Bogdan and Conti, Massimo and Gey, Thomas and Gregoire, Marc and Copin, Marie-Christine and Devos, Patrick and Chahine, Bachar and Porte, Henri and Lassalle, Philippe},
	month = may,
	year = {2006},
	pmid = {16456138},
	keywords = {Humans, Female, Prospective Studies, Aged, Male, Middle Aged, Prognosis, Survival Analysis, Neoplasm Staging, Disease Progression, Sensitivity and Specificity, Analysis of Variance, GPI-Linked Proteins, Diagnosis, Differential, Area Under Curve, Asbestosis/metabolism/mortality/*pathology, Biomarkers, Tumor/analysis, Membrane Glycoproteins/analysis/*metabolism, Mesothelioma/blood/mortality/*pathology, Osteopontin, Pleural Effusion, Malignant/*diagnosis/metabolism/mortality, Pleural Neoplasms/blood/mortality/*pathology, Sialoglycoproteins/*metabolism, Solubility},
	pages = {1155--1160}
}
Downloads: 0